Eve Personal Exoskeleton
About
About Eve Personal Exoskeleton
Eve is Wandercraft's self-balancing personal exoskeleton for hands-free upright mobility in daily environments. Twelve motors support multidirectional movement while the control system continuously manages balance. The device is individually fitted and is intended for use after the wearer and a companion complete Wandercraft's assessment and certification process.
Published fitting limits include a user weight up to 100 kg and height up to 1.94 m, subject to additional leg, pelvis and joint-mobility ranges. Wandercraft states about four hours of battery operation. Eve is designed for home and community mobility with a trained companion; clinical eligibility, fitting, training, terrain limits and local regulatory availability remain part of the individual deployment decision.
Timeline
- Wandercraft completes acquisition of Ekso Bionics operating business
2026-10-01 - Acquisition - Atalante X and EksoNR together support patients at more than 700 rehabilitation centers worldwide. Wandercraft intends to keep supporting Atalante X, EksoNR, Eve and Indego Personal. Both boards unanimously approved the transaction, combining Wandercraft’s EMEA position with Ekso’s U.S. clinical and commercial reach.
Source - Wandercraft commercially launches Eve exoskeleton in the U.S.
2026-09-17 - Product Launch - Eve is the first FDA-cleared personal exoskeleton without restrictions based on the neurological level of spinal cord injury, extending eligibility beyond previously cleared devices. National Seating & Mobility, Wandercraft's exclusive Complex Rehabilitation Technology distribution partner for Eve, will support evaluation, education, access and delivery through a network of more than 180 locations. Medicare covers qualifying personal exoskeletons as custom-fitted orthoses under HCPCS billing code K1007, with Department of Veterans Affairs access via USVetServ, workers' compensation programmes and self-pay financing options also in place.
Source - Wandercraft receives FDA clearance for Eve personal exoskeleton
2026-08-11 - Regulatory - Eve is intended for level indoor surfaces and level surfaces in immediately adjacent open-air areas such as patios and terraces, under the supervision of a specially trained companion. The clearance builds on Atalante X, Wandercraft's self-balancing rehabilitation exoskeleton used in more than 150 rehabilitation and research centres worldwide. Medicare has provided a reimbursement pathway for eligible personal exoskeleton users under DMEPOS billing code K1007 since 2024, with Wandercraft anticipating Eve could become eligible within 60 to 90 days.
Source
Context
Comparable Systems
- ANGEL SUIT H10
Angel Robotics - Exoskeleton
- ReWalk 7 Personal Exoskeleton
Lifeward / ReWalk Robotics - Exoskeleton